Illimis Therapeutics
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18 Heolleung-ro 569-gil, Seoul, 06376, S...Phone Number
+82 24456877Website
www.illimistx.comRevenue
$11.8 MillionIndustry
About Illimis Therapeutics
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimers. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.Explore more
SIC Code 87,873NAICS Code 54,541Show moreIllimis Therapeutics Org Chart
Illimis Therapeutics Tech Stack
A closer look at the technologies used by Illimis Therapeutics
Top Business Services Companies
Frequently Asked Questions Regarding Illimis Therapeutics
Sign Up For FreeTo access detailed company insights
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimers. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from e... Read More